Opendata, web and dolomites

SAVEBRAIN SIGNED

Proof of principle for a first in class neuroprotective therapy in stroke and other acute neurodegenerative conditions

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "SAVEBRAIN" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT MAASTRICHT 

Organization address
address: Minderbroedersberg 4-6
city: MAASTRICHT
postcode: 6200 MD
website: http://www.maastrichtuniversity.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 149˙993 €
 EC max contribution 149˙993 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) coordinator 51˙896.00
2    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 78˙097.00
3    MUCKE HERMANN AT (WIEN) participant 19˙999.00

Map

 Project objective

Stroke represents currently one of the largest – if not the largest - unmet medical need: It is the second leading cause of death and the leading cause of disability. In contrast to this high demand for effective treatments, there is only one drug available, a blood-clot dissolving agent. However, this drug is marginally effective has over 30 contra-indications, and bears an extremely high risk of causing fatal bleeding that 85% of all stroke patients are not treated with it. The needed innovation would be a drug which is broadly applicable, i.e. has no contraindication, can be given in all forms of stroke and already in the ambulance, is safe, i.e. bears no risk to cause secondary bleeding, is effective, i.e. reduces the brain infarct, increases survival and improves neurological outcomes for patients, has a different mechanism of action, i.e. is directly neuroprotective. Our therapeutic principle, discovered in the course of the ERC-ADG RadMed fulfils all above criteria and is also commercially an innovative approach because we reduce the risk by developing only a single compound by here combining three compounds that target the same disease mechanism but at different points. We thereby expect to dramatically reduce the likelihood risk of failure in our post-proof of concept (PoC) clinical development and commercialisation process. We here propose to conduct the final step, the PoC, before a first-in-man study in stroke. Our PoC plan has three major objectives: To complete an IPR FTPO and Foreground analysis, to chose the optimal compounds and complete phase III pre-clinical to provide PoC for a first-in-man trial in stroke, to then allow the work-out of a complete business plan including competitive analysis, development strategy, and commercial/business development strategy.

 Publications

year authors and title journal last update
List of publications.
2019 Ana I. Casas, Pamela W.M. Kleikers, Eva Geuss, Friederike Langhauser, Thure Adler, Dirk H. Busch, Valerie Gailus-Durner, Martin Hrabê de Angelis, Javier Egea, Manuela G. Lopez, Christoph Kleinschnitz, Harald H.H.W. Schmidt
Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke
published pages: 1772-1778, ISSN: 0021-9738, DOI: 10.1172/jci124283
Journal of Clinical Investigation 129/4 2020-04-03
2019 Ana I. Casas, Ahmed A. Hassan, Simon J. Larsen, Vanessa Gomez-Rangel, Mahmoud Elbatreek, Pamela W. M. Kleikers, Emre Guney, Javier Egea, Manuela G. López, Jan Baumbach, Harald H. H. W. Schmidt
From single drug targets to synergistic network pharmacology in ischemic stroke
published pages: 7129-7136, ISSN: 0027-8424, DOI: 10.1073/pnas.1820799116
Proceedings of the National Academy of Sciences 116/14 2020-04-03
2017 Ana I. Casas, Eva Geuss, Pamela W. M. Kleikers, Stine Mencl, Alexander M. Herrmann, Izaskun Buendia, Javier Egea, Sven G. Meuth, Manuela G. Lopez, Christoph Kleinschnitz, Harald H. H. W. Schmidt
NOX4-dependent neuronal autotoxicity and BBB breakdown explain the superior sensitivity of the brain to ischemic damage
published pages: 12315-12320, ISSN: 0027-8424, DOI: 10.1073/pnas.1705034114
Proceedings of the National Academy of Sciences 114/46 2019-04-03

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAVEBRAIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAVEBRAIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

TWISTRONICS (2020)

Probing topological valley currents by angular layer alignment in van der Waals heterostructures

Read More  

DINEMOS (2019)

Discovery of New Molecular Semiconductors

Read More  

3DPBio (2020)

Computational Models of Motion for Fabrication-aware Design of Bioinspired Systems

Read More